Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

692
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
692
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.4K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.4K
Bone Disorders01:29

Bone Disorders

8.8K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
8.8K
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

4.9K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
4.9K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

1000
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1000
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

1.4K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mapping inequalities in rheumatology care in Europe: the first edition of the EULAR RheumaFacts project.

Annals of the rheumatic diseases·2026
Same author

Application of the SLERPI scoring system as a classification tool in systemic lupus erythematosus and its performance in early disease recognition.

Rheumatology international·2026
Same author

Fluvoxamine modulates interferon and inflammatory gene signatures in immune cell lines: an <i>in silico</i> transcriptomic analysis for lupus repurposing.

Immunopharmacology and immunotoxicology·2026
Same author

Beyond screening for pulmonary arterial hypertension: The DETECT score is a potential promising prediction tool for all-cause mortality in systemic sclerosis: Analysis from the EUSTAR database.

Journal of autoimmunity·2026
Same author

The incidence of interstitial lung disease in patients with systemic sclerosis: rate, risk factors and prognostic implications in a EUSTAR cohort analysis (CP 133).

Annals of the rheumatic diseases·2026
Same author

Low vaccination uptake and attitudes towards COVID-19, influenza, and Streptococcus pneumoniae vaccines: a cross-sectional survey of patients with rheumatic diseases.

Rheumatology international·2025

Related Experiment Video

Updated: Apr 20, 2026

Author Spotlight: Developing a Rat Model for Weight-Bearing Intervention to Investigate Osteonecrosis of the Femoral Head
05:55

Author Spotlight: Developing a Rat Model for Weight-Bearing Intervention to Investigate Osteonecrosis of the Femoral Head

Published on: September 27, 2024

1.1K

[Glucocorticoid induced osteoporosis].

Branimir Anić, Miroslav Mayer

    Reumatizam
    |November 28, 2014
    PubMed
    Summary

    Glucocorticoid therapy commonly causes secondary osteoporosis by impairing bone formation and increasing resorption. Prevention and treatment involve minimizing glucocorticoid dosage, supplementation, and bisphosphonate therapy for high-risk patients.

    Area of Science:

    • Endocrinology
    • Bone Biology
    • Pharmacology

    Context:

    • Secondary osteoporosis is a significant complication of glucocorticoid therapy.
    • Glucocorticoids disrupt the delicate balance of bone remodeling, affecting both formation and resorption processes.
    • Osteoblast dysfunction and apoptosis are key mechanisms leading to bone loss.

    Purpose:

    • To elucidate the mechanisms by which glucocorticoids induce osteoporosis.
    • To outline strategies for preventing and managing glucocorticoid-induced bone loss.
    • To highlight current therapeutic approaches for patients at high fracture risk.

    Summary:

    • Glucocorticoid therapy adversely impacts bone remodeling by decreasing osteoblast activity and promoting apoptosis, leading to reduced bone mineral density and increased fracture risk.

    More Related Videos

    Preparation Of Gushukang GSK Granules for In Vivo and In Vitro Experiments
    06:16

    Preparation Of Gushukang GSK Granules for In Vivo and In Vitro Experiments

    Published on: May 9, 2019

    8.2K
    Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats
    08:56

    Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats

    Published on: April 7, 2023

    1.5K

    Related Experiment Videos

    Last Updated: Apr 20, 2026

    Author Spotlight: Developing a Rat Model for Weight-Bearing Intervention to Investigate Osteonecrosis of the Femoral Head
    05:55

    Author Spotlight: Developing a Rat Model for Weight-Bearing Intervention to Investigate Osteonecrosis of the Femoral Head

    Published on: September 27, 2024

    1.1K
    Preparation Of Gushukang GSK Granules for In Vivo and In Vitro Experiments
    06:16

    Preparation Of Gushukang GSK Granules for In Vivo and In Vitro Experiments

    Published on: May 9, 2019

    8.2K
    Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats
    08:56

    Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats

    Published on: April 7, 2023

    1.5K
  • Preventive measures include using the lowest effective glucocorticoid dose, calcium and vitamin D supplementation, and hormone replacement therapy.
  • Physical activity is encouraged, and antiresorptive drugs, particularly bisphosphonates, are the first-line treatment for high-risk individuals.

    • Impact:

    • Provides a comprehensive overview of glucocorticoid-induced osteoporosis, aiding clinicians in patient management.
    • Emphasizes the importance of proactive prevention and early intervention strategies.
    • Informs therapeutic decisions, guiding the use of bisphosphonates as a primary treatment for at-risk populations.